Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide and Envafolimab in PD-1 Resistant NSCLC
NCT05068427Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Nov 2021
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat in non-small cell lung cancer (NSCLC), sponsored by Akeso, Inc.. Started Nov 2021; status: completed.
02
Drugs
tucidinostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05068427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05068427.